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The last decade has seen a major surge in new 
therapies developed based on understanding 
the immune system and how each component 
interacts with another to lead to disease. The 
targeted biologic therapies based on these 
insights made a significant impact on how we 
treat our patients, and the expectations we as 
clinicians and patients have from our therapies. 
Biologics currently in use and being 
developed show increasing growth, and from 
monoclonal agents against cytokines to cell 
modifiers to vaccines, they are here to stay.
Along with this increasing presence of 
biologics in our every day treatment of our 
patients, the need to learn about them and 
follow the development of new agents has 
intensified. In this climate, a journal focused on 
biologics and their role in disease management 
is a welcome sight. 
Biologics in Therapy is a fully open access, 
internationally peer-reviewed, rapid publication 
journal with an emphasis on the publication of 
high-quality original research and review articles 
covering preclinical, clinical (phase I-IV), and 
post-marketing studies on new and existing 
therapies using biological products including 
vaccines, blood and blood components, 
allergenics, somatic cells, gene therapy, tissues, 
and recombinant therapeutic proteins. The 
target is the broad audience of pharmaceutical 
and healthcare professionals caring for patients, 
and thinking about how to improve what we 
provide as healthcare professionals every day.
Open access is possibly the way of the 
future in publishing; it has been growing, and 
funders and institutions have recognized that 
the funding models that support scholarly 
communication need to evolve to keep pace. 
There are now several institutions that are 
leading the way and have already set up central 
funds for their authors to use when publishing 
in open access journals.
Open access provides everything we are used 
to getting from journals and more by making 
access anon-problem, helping disseminate 
important information as easily as possible to as 
wide an audience as possible.
Biologics in Therapy will be a welcome 
addition to our armamentarium in educating 
ourselves and our patients on the latest biologic 
therapies available. 
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